Ovarian Hyperstimulation Syndrome Prevention Strategies: Individualizing Gonadotropin Dose

ABSTRACT

The choice of the gonadotropin starting dose is an important parameter to prevent the onset of ovarian hyperstimulation syndrome (OHSS). The vast majority of studies available propose decreasing the gonadotropin starting dose, but conflicting results confirm that simply reducing the dose is not sufficient to prevent OHSS. True and dependable individualization of the gonadotropin starting dose is not yet possible. Attempts have been made to select parameters that predict ovarian response and to model them in a scoring system or algorithm that would result in a recommended gonadotropin starting dose. The CONSORT (Consistency in r-FSH starting doses for individualized treatment) dosing algorithm individualizes recombinant human follicle-stimulating hormone doses for assisted reproduction technologies, assigning 37.5-IU increments according to easily available patient characteristics (basal follicle-stimulating hormone, body mass index, age, and antral follicle count) that have been proven to accurately predict ovarian response to ovarian stimulation. The use of the CONSORT algorithm achieved an adequate oocyte yield and good pregnancy rates in a preliminary study. Results of a prospective randomized study are awaited to see if this tool would allow individualization of the gonadotropin starting dose.

KEYWORDS

Ovarian hyperstimulation syndrome - gonadotropin - individualization

REFERENCES

• 1 Marci R, Senn A, Dessole S et al.. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.  Fertil Steril. 2001;  75(6) 1131-1135
• 2 Tan S L, Child T J, Cheung A P et al.. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment.  J Assist Reprod Genet. 2005;  22(2) 81-88
• 3 Latin-American Puregon IVF Study Group . A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization.  Fertil Steril. 2001;  76(5) 950-956
• 4 Out H J, Lindenberg S, Mikkelsen A L et al.. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.  Hum Reprod. 1999;  14(3) 622-627
• 5 Out H J, Rutherford A, Fleming R et al.. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction.  Hum Reprod. 2004;  19(1) 90-95
• 6 Wikland M, Bergh C, Borg K et al.. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.  Hum Reprod. 2001;  16(8) 1676-1681
• 7 Yong P Y, Brett S, Baird D T, Thong K J. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.  Fertil Steril. 2003;  79(2) 308-315
• 8 Forman R G, Frydman R, Egan D, Ross C, Barlow D H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.  Fertil Steril. 1990;  53(3) 502-509
• 9 Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction.  Fertil Steril. 2002;  77(4) 711-714
• 10 Filicori M, Cognigni G E, Samara A et al.. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction.  Hum Reprod Update. 2002;  8(6) 543-557
• 11 Lee K L, Couchman G M, Walmer D K. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.  J Assist Reprod Genet. 2005;  22(1) 37-40
• 12 Filicori M, Cognigni G E, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.  Fertil Steril. 2005;  84(2) 394-401
• 13 Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.  Hum Reprod. 2009;  24(11) 2910-2916
• 14 Homburg R. The management of infertility associated with polycystic ovary syndrome.  Reprod Biol Endocrinol. 2003;  1 109
• 15 Rongières-Bertrand C, Olivennes F, Righini C et al.. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.  Hum Reprod. 1999;  14(3) 683-688
• 16 Pelinck M J, Vogel N E, Arts E G, Simons A H, Heineman M J, Hoek A. Cumulative pregnancy rates after a maximum of nine cycles of modified natural cycle IVF and analysis of patient drop-out: a cohort study.  Hum Reprod. 2007;  22(9) 2463-2470
• 17 Popovic-Todorovic B, Loft A, Bredkjaeer H E, Bangsbøll S, Nielsen I K, Andersen A N. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard’ dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment.  Hum Reprod. 2003;  18(11) 2275-2282
• 18 Yih M C, Spandorfer S D, Rosenwaks Z. Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories.  Fertil Steril. 2005;  83(1) 24-29
• 19 van der Gaast M H, Eijkemans M J, van der Net J B et al.. Optimum number of oocytes for a successful first IVF treatment cycle.  Reprod Biomed Online. 2006;  13(4) 476-480
• 20 Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.  Hum Reprod Update. 2002;  8(6) 559-577
• 21 van Noord-Zaadstra B M, Looman C W, Alsbach H, Habbema J D, te Velde E R, Karbaat J. Delaying childbearing: effect of age on fecundity and outcome of pregnancy.  BMJ. 1991;  302(6789) 1361-1365
• 22 Wright V C, Schieve L A, Reynolds M A, Jeng G, Kissin D. Assisted reproductive technology surveillance—United States, 2001.  MMWR Surveill Summ. 2004;  53(1) 1-20
• 23 Abdalla H, Thum M Y. Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH.  Hum Reprod. 2006;  21(1) 171-174
• 24 Verberg M F, Eijkemans M J, Macklon N S, Heijnen E M, Fauser B C, Broekmans F J. Predictors of low response to mild ovarian stimulation initiated on cycle day 5 for IVF.  Hum Reprod. 2007;  22(7) 1919-1924
• 25 Broekmans F J, Kwee J, Hendriks D J, Mol B W, Lambalk C B. A systematic review of tests predicting ovarian reserve and IVF outcome.  Hum Reprod Update. 2006;  12(6) 685-718
• 26 Bancsi L F, Broekmans F J, Looman C W, Habbema J D, te Velde E R. Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization.  Fertil Steril. 2004;  81(1) 35-41
• 27 Bancsi L F, Broekmans F J, Mol B W, Habbema J D, te Velde E R. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis.  Fertil Steril. 2003;  79(5) 1091-1100
• 28 Popovic-Todorovic B, Loft A, Lindhard A, Bangsbøll S, Andersson A M, Andersen A N. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram.  Hum Reprod. 2003;  18(4) 781-787
• 29 Fleming R, Deshpande N, Traynor I, Yates R W. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone.  Hum Reprod. 2006;  21(6) 1436-1441
• 30 Howles C M, Saunders H, Alam V, Engrand P. FSH Treatment Guidelines Clinical Panel . Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients.  Curr Med Res Opin. 2006;  22(5) 907-918
• 31 Olivennes F, Howles C M, Borini A CONSORT study group et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.  Reprod Biomed Online. 2009;  18(2) 195-204
• 32 Hohmann F P, Macklon N S, Fauser B C. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.  J Clin Endocrinol Metab. 2003;  88(1) 166-173
• 33 Heijnen E M, Eijkemans M J, De Klerk C et al.. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial.  Lancet. 2007;  369(9563) 743-749
• 34 Baart E B, Martini E, Eijkemans M J et al.. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial.  Hum Reprod. 2007;  22(4) 980-988